Among American women, breast cancer is the most common cancer, after skin cancer. About 1 in 8 (12 percent) women in the U.S. will develop invasive breast cancer during their lifetime.
For 2018, the American Cancer Society estimates that:
Incidence rates of breast cancer are highest in non-Hispanic white women; however, breast cancer death rates are highest in African American women.
Source: American Cancer Society Breast Cancer Facts & Figures 2017-2018.
Breast cancer is the second leading cause of cancer death in women, surpassed only by lung cancer. Death rates from breast cancer have been declining since about 1989, with larger decreases in women younger than age 50. It is believed that earlier detection through screening and increased awareness, as well as improved treatment, has led to these decreases.
Today, there are more than 3.1 million breast cancer survivors in the U.S., including those still being treated and those who have completed treatment.
Source: American Cancer Society. Cancer Facts and Figures 2018. Atlanta, Ga: American Cancer Society; 2018.
The ACCC Metastatic Breast Cancer Project’s new online resource bank connects you to curated materials (webinars, articles, blogs, and more) to help close communication, education, and information gaps for patients and providers.
Search by topic, resource type (e.g., webinar, article, blog, tool), place in care continuum, or by the effective practices identified in the ACCC Metastatic Breast Cancer Project Workbook and latest case studies in Metastatic Breast Cancer: Effective Principles in Action.
Learn More & Explore the Resource Library
To support quality improvement (QI) projects in breast cancer, ACCC has partnered with Pfizer Global Medical Grants to award more than $1.8 million in funding to 15 projects that are aimed at improving the quality of breast cancer patient care. The projects will focus on conducting quality improvement initiatives that support increasing the rates of BRCA testing for patients with early stage or metastatic breast cancer. The grant awards are providing an opportunity for community oncology programs to implement initiatives that will address barriers to counseling and testing, and to utilize innovative approaches to extend best practices to a much larger patient population, including underserved minority patient groups.
The Association of Community Cancer Centers (ACCC) has joined with the Oncology Nursing Society (ONS) and The France Foundation to support a series of live Grand Rounds/Tumor Boards, “PARP Inhibitors: Advancing Personalized Medicine for Metastatic Breast Cancer Patients.”
ACCC member cancer programs are invited to participate in a live Grand Rounds program where a subject matter expert will travel to participating institutions to lead a one-hour accredited session. The Grand Rounds will provide the multidisciplinary cancer team with strategies to appropriately incorporate genetic testing and poly (ADP-ribose) polymerase (PARP) inhibitor therapy for patients with metastatic breast cancer (MBC).
U.S.-based cancer programs and practices participated in a quality improvement (QI) study by testing the “Dandelion Toolkit” designed to support clear communication, empowering both metastatic breast cancer patients and their healthcare providers.
ACCC is partnering with AXIS Medical Education in an educational research project to assess the value of a robust, independent, quality-focused educational intervention that aims to improve a community cancer program's quality measures related to management of patients with HER2+ breast cancer (all stages). Two ACCC-member Cancer Programs are participating in the project.